160 related articles for article (PubMed ID: 37095618)
1. Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Kim MC; Kwon SY; Choi JE; Kang SH; Bae YK
J Breast Cancer; 2023 Apr; 26(2):105-116. PubMed ID: 37095618
[TBL] [Abstract][Full Text] [Related]
2. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
3. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
5. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
Ünal Ç; Özmen T; İlgün AS; Ordu Ç; Özkurt E; Ak N; Alço G; Erdoğan İyigün Z; Kurt S; Duymaz T; Öztürk MA; Elbüken Çelebi F; Yararbaş K; Soybir G; Aktepe F; Özmen V
Breast Cancer (Dove Med Press); 2023; 15():659-669. PubMed ID: 37674872
[TBL] [Abstract][Full Text] [Related]
6. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
[TBL] [Abstract][Full Text] [Related]
7. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.
Song R; Lee DE; Lee EG; Lee S; Kang HS; Han JH; Lee KS; Sim SH; Chae H; Kwon Y; Woo J; Jung SY
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760420
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre.
Davey MG; Ryan ÉJ; Abd Elwahab S; Elliott JA; McAnena PF; Sweeney KJ; Malone CM; McLaughlin R; Barry MK; Keane MM; Lowery AJ; Kerin MJ
Breast J; 2021 Jun; 27(6):521-528. PubMed ID: 33709552
[TBL] [Abstract][Full Text] [Related]
10. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
[TBL] [Abstract][Full Text] [Related]
11. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
12. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
15. Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer.
Alshamsan B; Alshibany A; Elshenawy MA; Badran A; Elhassan T; Ajarim D; Alsayed A; Suleman K; Al-Tweigeri T
Cancer Manag Res; 2021; 13():9411-9420. PubMed ID: 35002318
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
17. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
18. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.
Onoda T; Yamauchi H; Yagata H; Tsugawa K; Hayashi N; Yoshida A; Suzuki K; Sakurai O; Nakamura S
Breast Cancer; 2015 Jul; 22(4):406-12. PubMed ID: 24081457
[TBL] [Abstract][Full Text] [Related]
19. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
20. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]